Sees FY25 revenue $5.6B-$6.0B, consensus $5.92B. Edwards Lifesciences (EW) enters 2025 in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement, or TAVR, and Transcatheter Mitral and Tricuspid Therapies, or TMTT, the continued long-term performance of Surgical, and future opportunities with Structural Heart Failure and Aortic Regurgitation, or AR. Highlights of today’s conference include: reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10%; advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025; TAVR growth reinforced by leading technology and EARLY TAVR; TMTT contribution accelerated by PASCAL, EVOQUE and SAPIEN M3; projecting 2025 constant currency sales growth of 8%-10%; TAVR sales of $4.1B-$4.4B; maintaining constant currency growth of 5%-7%, which assumes mid-year indication approval from EARLY TAVR; TMTT sales of $500M-$530M; constant currency growth of 50%-60%; increasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growth; mid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESS; TMTT increasing contribution to growth, reaching $2B by 2030; increasing contribution from new therapeutic areas including Structural Heart Failure and AR.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences price target raised to $88 from $85 at Barclays
- Edwards Lifesciences price target raised to $80 from $75 at RBC Capital
- Edwards Lifesciences announces presentation of one-year SAPIEN 3 data
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Edwards Lifesciences call volume above normal and directionally bullish
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
